Syndax Pharmaceuticals, Inc. today announced that on March 1, 2023 the Company granted an inducement award to purchase up to 15,200 shares of common stock to one new employee under the Company’s 2023 Inducement Plan.
|
WALTHAM, Mass., March 6, 2023 /PRNewswire/ --Syndax Pharmaceuticals Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on March 1, 2023 the Company granted an inducement award to purchase up to 15,200 shares of common stock to one new employee under the Company's 2023 Inducement Plan. The stock option has an exercise price per share of $24.86, the closing price of the Company's common stock on the Nasdaq Global Select Market on March 1, 2023 and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates. About Syndax Pharmaceuticals, Inc. Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective inhibitor of the Menin–KMT2A binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, both currently in pivotal trials. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn. Syndax Contact Sharon Klahre SNDX-G
SOURCE Syndax Pharmaceuticals, Inc. |
||
Company Codes: NASDAQ-NMS:SNDX |
View original content:
